NCT06538181View on ClinicalTrials.gov

Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 13, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

February 28, 2029

Conditions
E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic SyndromeVEXASVexas Syndrome
Interventions
DRUG

Pacritinib

Starting dose is 200 mg twice per day by mouth. Dose level -1 is 100 mg twice per day by mouth.

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Swedish Orphan Biovitrum
All Listed Sponsors
collaborator

Swedish Orphan Biovitrum

INDUSTRY

lead

Washington University School of Medicine

OTHER